Pain, Postoperative
Conditions
Keywords
Dexmedetomidine, fentanyl, analgesia,Sleeve Gastrectomy
Brief summary
Dexmedetomidine (Dex) activates the α2 adrenergic receptor that is present within the locus coeruleus, leading to anxiolysis, hypnosis, analgesia, and sedation. We conducted our research to compare the effects of fentanyl and DEX on the postoperative analgesic profile and complications in morbidly obese patients after sleeve gastrectomy.
Detailed description
The participants were assigned to two groups of equal size (32 patients in each group) by the use of computer-generated numbers and sealed opaque envelopes. The participants allocated to the DEX group, also known as Group D, received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal. The patients assigned to the fentanyl group (referred to as Group F) were administered fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
Interventions
DRUGDexmedetomidine
received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.
DRUGFentanyl
fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
Sponsors
Helwan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
double
Eligibility
Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* body mass index (BMI) of 35 kg/m2 or more. * American Society of Anesthesiology (ASA) physical status of II-III. * all participants would have a laparoscopic sleeve gastrectomy (LSG).
Exclusion criteria
* allergy to α2 -adrenergic agonist. * kidney, liver, neuromuscular disorders, and cardiac disease. * or patients on opioid medications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| visual analogue score | from arrival to PACU until 12 hours after surgery | visual analogue pain score (VAS) from 0-10 (0: no pain, 10: the worst pain). It was assessed in post anesthesia care unit ( PACU) and every 2 hours for 12 hours postoperatively |
Secondary
| Measure | Time frame |
|---|---|
| The time of the first analgesic request | first postoperative day |
| the total opioid dose consumed during the first 12 hours postoperatively | 12 hours after surgery |
| incidence of nausea and vomiting | 2 hours after surgery |
Countries
Egypt
Outcome results
None listed